NCT00395551已完成1 期
A Single Center Study of the Safety and Efficacy of Multiple Intravitreal Injections of Ranibizumab in Subjects With CNV Secondary to Causes Other Than AMD.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
- 主要终点
- The primary outcome measures for safety and tolerability
研究概览
简要总结
The purpose of this study is to determine whether ranibizumab is effective in the treatment of choroidal neovascularization secondary to causes other then wet macular-degeneration.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Factorial
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •active choroidal neovascularization
排除标准
- •pregnancy,age-related macular degeneration, current eye infection or recent eye surgery, participating in other eye studies
研究组 & 干预措施
ranibizumab
Active Comparator
ranibizumab 0.5mg intravitreal injection
干预措施: ranibizumab (Drug)
结局指标
主要结局
The primary outcome measures for safety and tolerability
时间窗: Mean change in visual acuity from baseline to 6 months & 12 months
次要结局
- The secondary outcome measures for efficacy(Mean change in visual acuity from baseline to 6 & 12 months. Change in retinal thickness from baseline to week 1, month 1, 2, 3, 6, & 12 measured by OCT. Change in area of CNV from baseline to month 3, 6 & 12 measured by FA)
研究者
相似试验
终止
3 期
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKECKDCardiac DiseaseCardiopulmonary BypassChronic Kidney DiseaseNCT05746559Alexion Pharmaceuticals, Inc.555
已完成
2 期
A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating PolyradiculoneuropathyChronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)NCT03861481UCB Biopharma S.P.R.L.34
已完成
3 期
A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or SulfasalazineArthritis, RheumatoidNCT01689532Janssen Pharmaceutical K.K.122
Unknown
2 期
A Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated LiposarcomaLiposarcomas, DedifferentiatedLiposarcoma - Well DifferentiatedSoft-Tissue SarcomaMixed Type LiposarcomaNCT03096912Assaf-Harofeh Medical Center30
Unknown
2 期
A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated LiposarcomaSoft Tissue SarcomaLiposarcomaNCT02571829Hadassah Medical Organization30